JP2025506206A5 - - Google Patents
Info
- Publication number
- JP2025506206A5 JP2025506206A5 JP2024547861A JP2024547861A JP2025506206A5 JP 2025506206 A5 JP2025506206 A5 JP 2025506206A5 JP 2024547861 A JP2024547861 A JP 2024547861A JP 2024547861 A JP2024547861 A JP 2024547861A JP 2025506206 A5 JP2025506206 A5 JP 2025506206A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- cancer
- compound according
- compound
- cycloalkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263310400P | 2022-02-15 | 2022-02-15 | |
| US63/310,400 | 2022-02-15 | ||
| US202263341238P | 2022-05-12 | 2022-05-12 | |
| US63/341,238 | 2022-05-12 | ||
| PCT/US2023/013118 WO2023158679A2 (en) | 2022-02-15 | 2023-02-15 | Thiostrepton-inspired compounds for treatment of cancer and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506206A JP2025506206A (ja) | 2025-03-07 |
| JP2025506206A5 true JP2025506206A5 (cg-RX-API-DMAC7.html) | 2026-02-19 |
Family
ID=87579015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547861A Pending JP2025506206A (ja) | 2022-02-15 | 2023-02-15 | がん治療のためのチオストレプトンから着想された化合物及びその調製 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250144078A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4479390A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506206A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119301105A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023222756A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3252219A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202342492A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023158679A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024044744A2 (en) * | 2022-08-26 | 2024-02-29 | Wake Forest University Health Sciences | Peroxiredoxin 3 inhibitors and methods of use for treating cancer |
| US20260069580A1 (en) * | 2022-08-26 | 2026-03-12 | Wake Forest University Health Sciences | Peroxiredoxin 3 inhibitors and methods of use for treating cancer |
| WO2024044751A2 (en) * | 2022-08-26 | 2024-02-29 | Wake Forest University Health Sciences | Peroxiredoxin 3 inhibitors and methods of use for treating cancer |
| WO2024173644A2 (en) * | 2023-02-15 | 2024-08-22 | Rs Oncology, Llc | Select thiostrepton-inspired compounds for treatment of cancer and preparation thereof |
| TW202613105A (zh) * | 2024-06-21 | 2026-04-01 | 美商Rs腫瘤學有限責任公司 | 用於治療癌症之經修飾之硫鏈絲菌肽啟發之化合物及其製備 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| EP2576595B1 (en) | 2010-05-30 | 2016-12-21 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for anticancer compounds |
| US9173952B2 (en) | 2010-05-30 | 2015-11-03 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for antimicrobials |
| WO2017095751A1 (en) * | 2015-12-02 | 2017-06-08 | Partikula Llc | Compositions and methods for modulating cancer cell metabolism |
| EP3685846A1 (en) * | 2019-01-24 | 2020-07-29 | Genethon | Use of thiostrepton or its derivatives for the treatment of genetic diseases linked to a protein conformational disorder |
-
2023
- 2023-02-15 CA CA3252219A patent/CA3252219A1/en active Pending
- 2023-02-15 WO PCT/US2023/013118 patent/WO2023158679A2/en not_active Ceased
- 2023-02-15 AU AU2023222756A patent/AU2023222756A1/en active Pending
- 2023-02-15 JP JP2024547861A patent/JP2025506206A/ja active Pending
- 2023-02-15 EP EP23756836.5A patent/EP4479390A4/en active Pending
- 2023-02-15 TW TW112105454A patent/TW202342492A/zh unknown
- 2023-02-15 CN CN202380027720.4A patent/CN119301105A/zh active Pending
- 2023-02-15 US US18/837,725 patent/US20250144078A1/en active Pending